Mergers & Acquisitions ·
Senti Biosciences Holdings, Inc. entered into a merger agreement on July 14, 2026, with an affiliate of its largest…
SNTISenti Biosciences Holdings, Inc.
Senti Biosciences Holdings, Inc. entered into a merger agreement on July 14, 2026, with an affiliate of its largest stockholder, Celadon Partners, to sell substantially all of its business and pipeline. The company will remain public but streamlined, focusing on its Regulator Dial technology platform for Rett syndrome and tumor-infiltrating lymphocyte therapies. Stockholders will receive contingent value rights (CVRs) that may provide cash payments totaling up to $60 million based on regulatory and commercial milestones for SENTI-202. The transaction is subject to stockholder approval and is expected to close in the third quarter of 2026. Senti Biosciences is a synthetic biology company developing controllable therapies for gene and cell therapy.